Board of Directors

Our experienced board members work closely with the Dermira leadership team to foster a culture of accountability and responsibility.

They support our efforts to identify, develop and commercialize truly novel therapies for patients and the healthcare professionals who serve them. Our board represents a diverse collection of academic, business and government expertise.

Eugene A. Bauer, M.D. Founder & Chief Medical Officer, Dermira

Founder & Chief Medical Officer, Dermira

Dr. Bauer is a co-founder of Dermira, our Chief Medical Officer and a member of our board of directors. Prior to founding Dermira, he served as a member of Peplin’s board of directors, and its President and Chief Medical Officer, until its acquisition by LEO Pharma. He was also the Chief Executive Officer of Neosil Inc., and a co-founder and member of the board of directors at Connetics. Before initiating his career in industry, he served as the Dean of the Stanford University School of Medicine and as Chair of the Department of Dermatology at the Stanford University School of Medicine. He is a Lucy Becker Professor, Emeritus, in the School of Medicine at Stanford University, a position he has held since 2002.

Dr. Bauer has served on the boards of directors of a number of public and private companies. He is currently a member of the boards of directors of Aevi Genomic Medicine., Inc. (formerly Medgenics, Inc.), First Wave Technologies, Inc., Cerecor, Inc. and Kadmon Corporation. He previously served as a member of the boards of directors of Dr. Tattoff, Inc., Protalex, Inc., Vyteris, Inc., Peplin, PetDRx, Inc., Arbor Vita Corp., Patient Safety Technologies, Inc., MediSync Bioservices and Modigene Inc. (renamed PROLOR Biotech, Inc.).

Dr. Bauer was a U.S. National Institutes of Health (NIH)-funded investigator for 25 years and has served on review groups for the NIH. He has been elected to several societies, including the National Academy of Medicine of the United States and currently serves as a director of the American Dermatological Association, Inc. Dr. Bauer received a B.S. in medicine and an M.D. from Northwestern University.

Emmanuel Caeymaex Executive Vice President, Immunology Patient Value Unit Head, UCB S.A

Executive Vice President, Immunology Patient Value Unit Head, UCB S.A

Mr. Caeymaex joined Dermira as a director in January 2017. He is currently at UCB serving as Executive Vice President, Immunology Patient Value Unit Head, where he leads the worldwide development and commercialization of innovative patient-oriented solutions for people suffering from various auto-immune disorders and skin conditions. Prior to his current role, Mr. Caeymaex served in various positions at UCB or its affiliated companies, including as Vice President, Senior Global Project Leader of the CIMZIA® Global Patient Solutions team at UCB Biopharma SPRL from June 2011 to February 2015 and as President of UCB Japan Co Ltd. from September 2006 to June 2011.

Mr. Caeymaex received a Business Engineering MSc degree from the University of Louvain, Belgium, and a Master’s in International Management from the Community of European Management Schools.

David E. Cohen, M.D., M.P.H. Professor, Vice Chairman of Clinical Affairs, Department of Dermatology, New York University School of Medicine

Professor, Vice Chairman of Clinical Affairs, Department of Dermatology, New York University School of Medicine

Dr. Cohen joined Dermira as a director in 2014 after previously serving as a scientific advisor since our inception. He has held a variety of positions at the New York University School of Medicine, including Charles C. and Dorothea E. Harris Professor of Dermatology, Vice Chairman of Clinical Affairs, Chief of Allergy and Contact Dermatitis, and Director of Occupational and Environmental Dermatology. He has served as a lecturer of Environmental Sciences at the Columbia University School of Public Health, and has been an attending physician at the Ronald O. Perelman Department of Dermatology at the Tisch Hospital at New York University Medical Center and at Bellevue Hospital Center.

Dr. Cohen is currently serving as President of the American Dermatological Association. He has served as a clinical consultant to numerous companies and on the boards and committees of a number of professional organizations, including as President of the American Contact Dermatitis Society, as a founding board member of the American Acne and Rosacea Society, as President of the Dermatology Section of the New York Academy of Medicine and on several committees of the American Academy of Dermatology and the American College of Allergy, Asthma and Immunology. He is also a member of the editorial board of Journal of Drugs in Dermatology and the editorial advisory boards of Dermatitis and Skin and Allergy News. He also served on the boards of directors of Vyteris and Connetics.

Dr. Cohen earned a B.S. in biomedical science from the City University of New York, an M.D. from the State University of New York at Stony Brook School of Medicine, and an M.P.H. in environmental science from Columbia University School of Public Health.

Fred Craves, Ph.D. Investment Partner, Managing Director and Founder, Bay City Capital

Investment Partner, Managing Director and Founder, Bay City Capital

Dr. Craves has been a director of Dermira since 2010. He is an investment partner, a Managing Director and a co-founder of Bay City Capital (BCC), and has served as a member of the board of directors and Chairman of the executive committee of BCC since June 1997. Prior to founding BCC, he founded Burrill & Craves, a merchant bank focused on biotechnology and emerging pharmaceutical companies. Dr. Craves served as Executive Vice President of Schering Berlin, Inc. and Chief Executive Officer and President of Berlex Laboratories, Inc. He was also the founding Chairman of the board of directors and Chief Executive Officer of Codon Devices, Inc. and co-founder of Creative Biomolecules.

Dr. Craves is currently a member of the boards of directors of Madrigal Pharmaceuticals, Reset Therapeutics and Twist Bioscience. He previously served as a member of the boards of directors of VIA Pharmaceuticals, Inc. and Poniard Pharmaceuticals, Inc. He currently serves as a member of The J. David Gladstone Institutes’ Advisory Council.

Dr. Craves earned a B.S. in biology from Georgetown University, an M.S. in biochemical pharmacology from Wayne State University, and a Ph.D. in pharmacology and experimental toxicology from the University of California, San Francisco.

Matthew Fust Former Executive Vice President and Chief Financial Officer, Onyx Pharmaceuticals

Former Executive Vice President and Chief Financial Officer, Onyx Pharmaceuticals

Mr. Fust joined Dermira as a director in 2014. He is a board member and advisor to life sciences companies. Mr. Fust retired as Executive Vice President and Chief Financial Officer at Onyx Pharmaceuticals, where he served until its acquisition by Amgen. Prior to joining Onyx, he was Chief Financial Officer at Jazz Pharmaceuticals, Inc., Perlegen Sciences, Inc. and ALZA Corporation. Previously, he was a manager in the healthcare strategy practice at Andersen Consulting. Mr. Fust serves as a member of the board of directors of Atara Biotherapeutics, Inc., MacroGenics, Inc., Sunesis Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical, Inc.

Mr. Fust holds a B.A. in accounting from the University of Minnesota and an M.B.A. from the Stanford Graduate School of Business.

Mark McDade Partner, Qiming Venture Capital US

Partner, Qiming Venture Capital US

Mr. McDade joined Dermira as a director in 2014. He is currently a founding partner of Qiming Venture Capital US. Prior to that, he served in various roles with UCB S.A., most recently as Executive Vice President, Chief Operating Officer. Prior to UCB, Mr. McDade served as Chief Executive Officer and on the board of directors of PDL BioPharma, Chief Executive Officer of Signature BioScience, co-founder, President and Chief Operating Officer at Corixa Corporation, and Chief Operating Officer of Boehringer Mannheim Therapeutics, the biopharmaceutical division of Corange Limited. He held numerous business development and general management positions at Sandoz Ltd. He is currently a director of Five Prime Therapeutics and Aimmune Therapeutics, Inc. and previously served on the board of directors of Cytokinetics.

Mr. McDade received a B.A. from Dartmouth College and an M.B.A. from Harvard Business School.

Jake Nunn Partner, New Enterprise Associates

Partner, New Enterprise Associates

Mr. Nunn has been a director of Dermira since 2011. He has been a Partner at New Enterprise Associates, Inc. (NEA) since June 2006. Prior to joining NEA, he served as a Partner and an analyst for the MPM BioEquities Fund, a life sciences fund at MPM Capital, L.P., a private equity firm. Previously, he was a healthcare research analyst and portfolio manager at Franklin Templeton Investments and an investment banker with Alex, Brown & Sons. Mr. Nunn currently also serves on the board of directors of Trevena, Inc.

Mr. Nunn received his A.B. in economics from Dartmouth College and his M.B.A. from the Stanford Graduate School of Business. He also holds the Chartered Financial Analyst designation and is a member of the CFA Society of San Francisco.

William Ringo Former Senior Advisor, Barclays Healthcare Group and Strategic Advisor to Sofinnova Ventures

Former Senior Advisor, Barclays Healthcare Group and Strategic Advisor to Sofinnova Ventures

Mr. Ringo joined Dermira as a director in 2014. He previously served as a senior advisor to Barclays Healthcare Group and as a strategic advisor to Sofinnova Ventures after retiring from Pfizer in 2010, where he was Senior Vice President of Business Development and Corporate Strategy. Prior to Pfizer, he served as an executive in residence at Warburg Pincus and Sofinnova Ventures, as President and Chief Executive Officer of Abgenix, Inc. and held a number of senior positions in the oncology and critical care, internal medicine, infectious disease and sales and marketing divisions at Eli Lilly & Company. Mr. Ringo is currently a member of the boards of directors of Assembly Biosciences, Inc., Immune Design Corp. and Sangamo Biosciences. He previously served as a member of the board of directors of Onyx Pharmaceuticals and Mirati Therapeutics.

Mr. Ringo received a B.S. in industrial management and an M.B.A. from the University of Dayton.

Kathleen Sebelius 21st Secretary of U.S. Department of Health and Human Services

21st Secretary of U.S. Department of Health and Human Services

Ms. Sebelius joined Dermira as a director in 2015. In 2016, she also joined the board of directors of Myovant Sciences, Ltd. Ms. Sebelius was Secretary of the U.S. Department of Health and Human Services from 2009 to 2014. As Secretary, she presided over 11 operating divisions, including the Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA) and National Institutes of Health (NIH), and an annual budget approaching $1 trillion. She also oversaw the passage and implementation of the Affordable Care Act, the most significant health reform in half a century.

Previously, Ms. Sebelius was Governor of Kansas, having been elected in 2002 and winning re-election in 2006. For the preceding eight years, Ms. Sebelius held the position of Kansas Insurance Commissioner and, from 1987-1995, she served four terms in the Kansas House of Representatives.

Ms. Sebelius holds a B.A. in political science from Trinity Washington University and a Master of Public Administration from the University of Kansas.

Thomas G. Wiggans Founder, Chief Executive Officer & Chairman of the Board of Directors, Dermira

Founder, Chief Executive Officer & Chairman of the Board of Directors, Dermira

Mr. Wiggans co-founded Dermira in 2010 and is our Chief Executive Officer and Chairman of our board of directors. He has over 30 years of experience in biopharmaceuticals. Prior to founding Dermira, he served as Chairman of the board of directors and Chief Executive Officer of Peplin, Inc. until Peplin’s acquisition by LEO Pharma A/S in 2009. Previously, he served as Chairman of the board of directors and Chief Executive Officer of Connetics Corporation until Connetics was acquired by Stiefel Laboratories, Inc. in 2006. Prior to Connetics, he served as President and Chief Operating Officer of CytoTherapeutics Inc. and in various management positions at Ares-Serono S.A., including President of its U.S. pharmaceutical operations and Managing Director of its U.K. pharmaceutical operations. He began his career with Eli Lilly and Company.

Mr. Wiggans has served on the boards of various industry organizations, educational institutions and private and public companies, including service on the boards of directors of Onyx Pharmaceuticals, Inc. until its acquisition by Amgen in 2013, Sangamo Biosciences, Inc. and Somaxon Pharmaceuticals, Inc.

In addition, he is a member of the board of directors of Biotechnology Innovation Organization (BIO), the world’s largest biotechnology trade association, and is a member of the board of trustees of the University of Kansas Endowment Association. He holds a B.S. in pharmacy from the University of Kansas and an M.B.A. from Southern Methodist University.